Regeneron: Phase III Success In Skin Cancer For Libtayo

Company Overview - Regeneron Pharmaceuticals has experienced a bearish trend since August, with shares losing over one third of their value [1] - In Q3 2024, the company reported revenues of $3.72 billion, reflecting an 11% year-over-year growth [1] Key Personnel - Brendan, a co-founder of 1200 Pharma, has a background in organic synthesis with a Ph.D. from Stanford University and has worked for major pharmaceutical companies and biotech startups [1]